The University of Chicago Header Logo

Philip Hoffman

Concepts (284)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
48
2021
1177
1.660
Why?
Lung Neoplasms
56
2023
2474
1.480
Why?
Antineoplastic Combined Chemotherapy Protocols
44
2025
2666
1.140
Why?
Advisory Committees
1
2022
95
0.720
Why?
Anemia, Hemolytic, Autoimmune
3
2009
12
0.550
Why?
Medical Oncology
1
2022
426
0.550
Why?
Vinblastine
13
2002
84
0.500
Why?
Paclitaxel
15
2008
484
0.470
Why?
Ifosfamide
12
2003
37
0.400
Why?
Combined Modality Therapy
26
2010
1754
0.360
Why?
Adenocarcinoma
12
2016
1215
0.340
Why?
Esophageal Neoplasms
7
2010
355
0.340
Why?
Cisplatin
15
2010
578
0.300
Why?
Survival Rate
22
2021
2057
0.300
Why?
Carcinoma, Squamous Cell
9
2019
1107
0.300
Why?
Antineoplastic Agents
12
2019
2386
0.290
Why?
Neoplasm Staging
23
2025
2087
0.290
Why?
Granulocyte Colony-Stimulating Factor
13
2008
158
0.280
Why?
Antineoplastic Agents, Phytogenic
8
2008
272
0.270
Why?
Camptothecin
4
2008
198
0.250
Why?
Aged
54
2025
21986
0.250
Why?
Neoplasm Recurrence, Local
4
2025
1538
0.250
Why?
Nucleosides
1
2006
22
0.230
Why?
Carboplatin
9
2025
331
0.220
Why?
Middle Aged
56
2025
29642
0.220
Why?
Biomarkers, Tumor
4
2023
1786
0.220
Why?
Carcinoma, Small Cell
3
2004
116
0.210
Why?
Antimetabolites, Antineoplastic
2
2020
246
0.200
Why?
Radiosurgery
2
2021
352
0.190
Why?
Humans
75
2025
98799
0.190
Why?
Breast Neoplasms
4
2025
3303
0.180
Why?
Adult
49
2025
29698
0.180
Why?
Female
61
2025
51997
0.180
Why?
United States Food and Drug Administration
1
2022
165
0.170
Why?
Male
58
2021
47475
0.170
Why?
Taxoids
7
2012
127
0.170
Why?
Loss of Function Mutation
1
2021
53
0.170
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2021
110
0.160
Why?
Dose-Response Relationship, Drug
11
2008
1949
0.160
Why?
Salvage Therapy
2
2019
241
0.150
Why?
Capecitabine
1
2020
103
0.150
Why?
Treatment Outcome
18
2025
9806
0.150
Why?
Antineoplastic Agents, Alkylating
3
1998
136
0.150
Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2019
20
0.150
Why?
Receptor, Fibroblast Growth Factor, Type 3
1
2019
22
0.150
Why?
Follow-Up Studies
10
2021
4049
0.150
Why?
Drug Resistance, Neoplasm
2
2021
671
0.140
Why?
Infusions, Intravenous
5
2002
403
0.140
Why?
Remission Induction
10
2011
764
0.140
Why?
Precision Medicine
2
2016
512
0.140
Why?
Ovarian Neoplasms
1
2025
829
0.140
Why?
Pyrazoles
1
2019
162
0.140
Why?
Aged, 80 and over
15
2021
7461
0.130
Why?
Benzamides
1
2019
260
0.130
Why?
Drug-Related Side Effects and Adverse Reactions
1
2020
220
0.130
Why?
Blood Group Incompatibility
2
2009
23
0.130
Why?
Erlotinib Hydrochloride
2
2015
88
0.130
Why?
Piperazines
1
2019
308
0.130
Why?
Stomach Neoplasms
2
2010
321
0.120
Why?
Pneumonectomy
4
2011
222
0.120
Why?
Maximum Tolerated Dose
6
2025
265
0.120
Why?
Protein Kinase Inhibitors
2
2012
642
0.110
Why?
Interferon-alpha
4
1997
191
0.110
Why?
Prognosis
9
2021
4139
0.110
Why?
Immunotherapy
1
2021
831
0.110
Why?
Carcinoma
1
1998
442
0.110
Why?
Fluorouracil
9
1998
543
0.110
Why?
Radiotherapy, Image-Guided
2
2012
66
0.100
Why?
Mesna
2
2008
8
0.100
Why?
Drug Administration Schedule
12
2003
837
0.100
Why?
Disease Progression
6
2023
1621
0.100
Why?
Blood Proteins
1
2014
147
0.100
Why?
Exanthema
1
2014
43
0.100
Why?
Leucovorin
8
1998
205
0.100
Why?
Neoplasm Metastasis
4
2012
1102
0.090
Why?
Organoplatinum Compounds
2
2004
95
0.090
Why?
Ketones
1
2012
15
0.090
Why?
Furans
1
2012
19
0.090
Why?
Carcinoma, Large Cell
1
2012
38
0.090
Why?
Glutamates
2
2014
85
0.090
Why?
Genetic Testing
1
2016
610
0.090
Why?
Proteomics
1
2014
282
0.090
Why?
Guanine
2
2014
194
0.080
Why?
Sirolimus
1
2012
181
0.080
Why?
Recombinant Proteins
6
2008
994
0.080
Why?
Thigh
1
1990
42
0.080
Why?
United States
2
2022
8387
0.080
Why?
ErbB Receptors
4
2015
517
0.070
Why?
Neutropenia
6
2008
211
0.070
Why?
Cladribine
1
2009
30
0.070
Why?
Transfusion Reaction
1
2009
15
0.070
Why?
Disease-Free Survival
5
2014
1196
0.070
Why?
Splenectomy
1
2009
50
0.070
Why?
Soft Tissue Neoplasms
1
1990
127
0.070
Why?
Antibodies, Monoclonal, Murine-Derived
1
2009
79
0.070
Why?
Lymphocyte Subsets
1
2009
71
0.070
Why?
Transplantation
1
2009
39
0.070
Why?
Vidarabine
1
2009
107
0.070
Why?
Immunoglobulins, Intravenous
1
2009
67
0.070
Why?
Lymphoproliferative Disorders
1
2009
105
0.070
Why?
Survival Analysis
7
2011
1530
0.070
Why?
Erythropoietin
1
2008
90
0.070
Why?
Rituximab
1
2009
138
0.070
Why?
Drug Tolerance
3
1996
59
0.060
Why?
Mutation
5
2023
4443
0.060
Why?
Quinazolines
1
2008
222
0.060
Why?
Adrenal Cortex Hormones
1
2009
308
0.060
Why?
Transplantation, Homologous
1
2009
1029
0.060
Why?
Thoracic Neoplasms
2
1998
63
0.060
Why?
Venous Thromboembolism
1
2009
178
0.060
Why?
Area Under Curve
2
2007
341
0.060
Why?
Histocompatibility
1
2006
71
0.060
Why?
Drug Therapy
1
2006
67
0.060
Why?
Dacarbazine
1
2006
104
0.060
Why?
Filgrastim
3
2008
56
0.050
Why?
Mifepristone
1
2025
59
0.050
Why?
Radiotherapy Dosage
4
2001
478
0.050
Why?
Gene Amplification
2
2019
142
0.050
Why?
Deoxycytidine
1
2025
218
0.050
Why?
Feasibility Studies
4
2008
818
0.050
Why?
Thionucleotides
1
2004
54
0.050
Why?
Cephalexin
1
2003
6
0.050
Why?
Immunosuppressive Agents
1
2009
1021
0.050
Why?
Purpura, Thrombotic Thrombocytopenic
1
2003
21
0.050
Why?
Neoplasms
3
1997
3382
0.050
Why?
Etoposide
4
2008
207
0.050
Why?
Brain Neoplasms
2
2008
845
0.050
Why?
Survival
1
2002
22
0.050
Why?
Proto-Oncogene Proteins c-bcl-2
1
2004
213
0.050
Why?
Antibodies, Monoclonal
1
2009
1422
0.050
Why?
Time Factors
3
2014
5586
0.050
Why?
Hematopoietic Stem Cell Transplantation
1
2009
979
0.040
Why?
Hematologic Neoplasms
1
2006
384
0.040
Why?
Ipilimumab
1
2021
69
0.040
Why?
Topoisomerase I Inhibitors
1
2001
35
0.040
Why?
Pemetrexed
2
2014
76
0.040
Why?
Ferredoxin-NADP Reductase
1
2020
15
0.040
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2020
28
0.040
Why?
Ceftizoxime
1
1999
3
0.040
Why?
Purpura, Thrombocytopenic
1
1999
6
0.040
Why?
Cephalosporins
1
1999
25
0.040
Why?
Thrombopoietin
1
1999
12
0.040
Why?
North America
1
2000
211
0.040
Why?
Megakaryocytes
1
1999
39
0.040
Why?
Europe
1
2000
360
0.040
Why?
Biopsy
1
2023
1226
0.040
Why?
Chemotherapy, Adjuvant
3
2015
527
0.040
Why?
Retrospective Studies
6
2021
11104
0.040
Why?
Agranulocytosis
2
1995
16
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2023
588
0.030
Why?
Topotecan
1
1998
47
0.030
Why?
Macrolides
2
2012
34
0.030
Why?
Chemoradiotherapy
2
2011
337
0.030
Why?
Clinical Trials, Phase II as Topic
2
1995
168
0.030
Why?
Esophagus
1
1998
113
0.030
Why?
Anti-Bacterial Agents
1
2003
885
0.030
Why?
Prospective Studies
2
2020
4837
0.030
Why?
Postoperative Complications
1
2009
2719
0.030
Why?
Germ-Line Mutation
1
2020
404
0.030
Why?
Expectorants
1
1996
5
0.030
Why?
Chicago
3
2014
1520
0.030
Why?
International Agencies
1
2015
35
0.030
Why?
Radiation-Sensitizing Agents
1
1996
99
0.030
Why?
Genotype
1
2020
1895
0.030
Why?
Injections, Intravenous
1
1995
215
0.030
Why?
Radiation Dosage
2
2011
233
0.030
Why?
Bone Marrow
4
1998
419
0.030
Why?
Cyclohexanecarboxylic Acids
1
1994
17
0.030
Why?
Hydroxyurea
4
1995
233
0.020
Why?
Cetuximab
1
2014
119
0.020
Why?
Esophagitis
3
1998
40
0.020
Why?
Lymphatic Metastasis
2
2012
519
0.020
Why?
Ethers, Cyclic
1
2012
8
0.020
Why?
Bridged-Ring Compounds
1
2012
16
0.020
Why?
Indoles
1
1994
340
0.020
Why?
Platinum
1
2012
68
0.020
Why?
Polymorphism, Single Nucleotide
1
2020
2577
0.020
Why?
Kaplan-Meier Estimate
1
2014
909
0.020
Why?
Four-Dimensional Computed Tomography
1
2011
18
0.020
Why?
Confidence Intervals
2
2003
221
0.020
Why?
Quality of Life
1
2020
1904
0.020
Why?
Double-Blind Method
1
2015
1793
0.020
Why?
Receptors, Growth Factor
1
2011
52
0.020
Why?
Genes, ras
1
2011
97
0.020
Why?
Administration, Oral
3
2001
677
0.020
Why?
Neoplastic Cells, Circulating
1
2011
78
0.020
Why?
Oncogene Proteins, Fusion
1
2011
137
0.020
Why?
Whole-Body Counting
1
1989
4
0.020
Why?
Gallium Radioisotopes
1
1989
18
0.020
Why?
Genomics
1
2016
914
0.020
Why?
Proto-Oncogene Proteins c-met
1
2011
199
0.020
Why?
Predictive Value of Tests
1
2014
1792
0.020
Why?
Darbepoetin alfa
1
2008
5
0.020
Why?
Hematinics
1
2008
12
0.020
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2008
18
0.020
Why?
Cohort Studies
3
2007
3242
0.020
Why?
Bone Marrow Transplantation
1
1989
287
0.020
Why?
Lymphoma, Non-Hodgkin
1
1990
262
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
369
0.020
Why?
Platinum Compounds
1
2007
29
0.020
Why?
Risk Factors
2
2014
6295
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2014
1105
0.020
Why?
Anemia
1
2008
135
0.020
Why?
Biomarkers
1
2014
2026
0.020
Why?
Drug Therapy, Combination
1
2008
766
0.020
Why?
Polyethylene Glycols
1
2008
383
0.010
Why?
Cyclophosphamide
3
1992
285
0.010
Why?
Leukemia
1
1987
310
0.010
Why?
Radiotherapy
1
2007
325
0.010
Why?
Image Processing, Computer-Assisted
1
2012
1305
0.010
Why?
Oligonucleotides, Antisense
1
2004
70
0.010
Why?
Neoadjuvant Therapy
1
2007
477
0.010
Why?
Bryostatins
1
2003
14
0.010
Why?
Lactones
1
2003
28
0.010
Why?
Premedication
1
2003
57
0.010
Why?
Young Adult
1
2015
7598
0.010
Why?
Sex Factors
2
2000
1144
0.010
Why?
Smoking
2
2000
676
0.010
Why?
Interleukin-6
1
2003
283
0.010
Why?
Blood Cell Count
1
2001
67
0.010
Why?
Radiation Pneumonitis
1
2001
23
0.010
Why?
Clinical Trials as Topic
2
1998
1128
0.010
Why?
Methotrexate
2
1992
229
0.010
Why?
Lung
1
1987
1409
0.010
Why?
Glucocorticoids
1
2003
371
0.010
Why?
Doxorubicin
2
1992
285
0.010
Why?
Drug Evaluation
2
1990
109
0.010
Why?
Creatinine
1
2001
315
0.010
Why?
Spirometry
1
2000
78
0.010
Why?
Coombs Test
1
1999
9
0.010
Why?
Forced Expiratory Volume
1
2000
138
0.010
Why?
Tumor Necrosis Factor-alpha
1
2003
712
0.010
Why?
Tomography, X-Ray Computed
1
1989
2680
0.010
Why?
Pilot Projects
2
1994
978
0.010
Why?
Hemolysis
1
1999
66
0.010
Why?
Antigen-Antibody Complex
1
1999
89
0.010
Why?
Platelet Count
1
1999
94
0.010
Why?
Isoantibodies
1
1999
138
0.010
Why?
Antibodies
1
1999
349
0.010
Why?
Thorax
1
1997
77
0.010
Why?
Isotretinoin
1
1997
22
0.010
Why?
Antidotes
1
1997
24
0.010
Why?
Regression Analysis
1
1998
578
0.010
Why?
Leukopenia
1
1997
66
0.010
Why?
Injections, Subcutaneous
1
1997
142
0.010
Why?
Hematopoietic Stem Cells
1
1999
330
0.010
Why?
Drug Synergism
1
1997
317
0.010
Why?
T-Lymphocytes
1
2003
1335
0.010
Why?
Incidence
1
2000
1798
0.010
Why?
Age Factors
1
2000
1976
0.010
Why?
Esophagogastric Junction
1
1995
36
0.010
Why?
Immunohistochemistry
1
1999
1818
0.010
Why?
Radiation Injuries
1
1996
160
0.010
Why?
Cyclohexenes
1
1994
5
0.010
Why?
Benzofurans
1
1994
12
0.010
Why?
Hematologic Diseases
1
1994
77
0.010
Why?
Palliative Care
1
1996
291
0.010
Why?
Radiotherapy, Adjuvant
1
1995
325
0.010
Why?
Thrombocytopenia
1
1995
194
0.010
Why?
Postoperative Care
1
1995
239
0.010
Why?
Research Design
1
1997
652
0.010
Why?
Clinical Trials, Phase I as Topic
1
1994
154
0.010
Why?
Procarbazine
1
1992
27
0.010
Why?
Immunologic Factors
1
1994
180
0.010
Why?
Vincristine
1
1990
102
0.000
Why?
Bleomycin
1
1990
102
0.000
Why?
Chi-Square Distribution
1
1990
361
0.000
Why?
Vindesine
1
1989
5
0.000
Why?
Radiotherapy, High-Energy
1
1989
43
0.000
Why?
Randomized Controlled Trials as Topic
1
1994
995
0.000
Why?
Mediastinal Neoplasms
1
1989
41
0.000
Why?
Radiography, Abdominal
1
1989
63
0.000
Why?
Prednisone
1
1990
252
0.000
Why?
Cytarabine
1
1990
218
0.000
Why?
Radionuclide Imaging
1
1989
183
0.000
Why?
Thiotepa
1
1989
32
0.000
Why?
Melphalan
1
1989
98
0.000
Why?
Actuarial Analysis
1
1987
60
0.000
Why?
Multivariate Analysis
1
1990
1007
0.000
Why?
Proportional Hazards Models
1
1990
925
0.000
Why?
Karyotyping
1
1987
220
0.000
Why?
Radiography, Thoracic
1
1989
331
0.000
Why?
Preoperative Care
1
1989
420
0.000
Why?
Acute Disease
1
1987
864
0.000
Why?
Hoffman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (284)
Explore
_
Co-Authors (56)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_